Literature DB >> 32212206

The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.

Joseph A Westrich1, Daniel W Vermeer2, Paul L Colbert2, William C Spanos2, Dohun Pyeon1,3.   

Abstract

The chemokine CXCL14 is a highly conserved, homeostatic chemokine that is constitutively expressed in skin epithelia. Responsible for immune cell recruitment and maturation, as well as impacting epithelial cell motility, CXCL14 contributes to the establishment of immune surveillance within normal epithelial layers. Furthermore, CXCL14 is critical to upregulating major histocompatibility complex class I expression on tumor cells. Given these important roles, CXCL14 is often dysregulated in several types of carcinomas including cervical, colorectal, endometrial, and head and neck cancers. Its disruption has been shown to limit critical antitumor immune regulation and is correlated to poor patient prognosis. However, other studies have found that in certain cancers, namely pancreatic and some breast cancers, overexpression of stromal CXCL14 correlates with poor patient survival due to increased invasiveness. Contributing to the ambiguity CXCL14 plays in cancer is that the native CXCL14 receptor remains uncharacterized, although several candidate receptors have been proposed. Despite the complexity of CXCL14 functions, it remains clear that this chemokine is a key regulatory factor in cancer and represents a potential target for future cancer immunotherapies.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  CXCL14; HPV; antitumor immunity; chemokine; immunotherapy

Mesh:

Substances:

Year:  2020        PMID: 32212206      PMCID: PMC7282946          DOI: 10.1002/mc.23188

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  141 in total

1.  The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors.

Authors:  R J Nibbs; E Kriehuber; P D Ponath; D Parent; S Qin; J D Campbell; A Henderson; D Kerjaschki; D Maurer; G J Graham; A Rot
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

3.  Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells.

Authors:  Yojiro Maehata; Shigeyuki Ozawa; Kyo Kobayashi; Yasumasa Kato; Fumihiko Yoshino; Chihiro Miyamoto; Kazuhito Izukuri; Eiro Kubota; Ryu-Ichiro Hata; Masaichi-Chang-Il Lee
Journal:  Free Radic Res       Date:  2010-08

4.  Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model.

Authors:  Tiffany Brake; Paul F Lambert
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

5.  Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor.

Authors:  Raffaella Bonecchi; Massimo Locati; Emanuela Galliera; Marisa Vulcano; Marina Sironi; Anna M Fra; Marco Gobbi; Annunciata Vecchi; Silvano Sozzani; Bodduluri Haribabu; Jo Van Damme; Alberto Mantovani
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

Review 6.  Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Authors:  David W Schoppy; John B Sunwoo
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-20       Impact factor: 3.722

7.  Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma.

Authors:  Chao Ye; Ran Tao; Qingyi Cao; Danhua Zhu; Yini Wang; Jie Wang; Juan Lu; Ermei Chen; Lanjuan Li
Journal:  Int J Oncol       Date:  2016-05-24       Impact factor: 5.650

8.  The epigenetic regulation of CXCL14 plays a role in the pathobiology of oral cancers.

Authors:  Ryuji Nakayama; Kazumune Arikawa; Ujjal K Bhawal
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

9.  CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection.

Authors:  Xiaoqin Ji; Zetian Shen; Benxin Zhao; Xi Yuan; Xixu Zhu
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

10.  CXC Chemokines Exhibit Bactericidal Activity against Multidrug-Resistant Gram-Negative Pathogens.

Authors:  Matthew A Crawford; Debra J Fisher; Lisa M Leung; Sara Lomonaco; Christine Lascols; Antonio Cannatelli; Tommaso Giani; Gian Maria Rossolini; Yohei Doi; David R Goodlett; Marc W Allard; Shashi K Sharma; Erum Khan; Robert K Ernst; Molly A Hughes
Journal:  MBio       Date:  2017-11-14       Impact factor: 7.867

View more
  16 in total

1.  CXCL14 exacerbates seizures by inhibiting GABA metabolism in epileptic mice.

Authors:  Mingyue Chen; Weiwei He; Xiaomi Ding; Shenglin Wang; Min Zhang; Xing Cao; Juan Tan; Guohui Jiang
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  p21 produces a bioactive secretome that places stressed cells under immunosurveillance.

Authors:  Ines Sturmlechner; Cheng Zhang; Chance C Sine; Erik-Jan van Deursen; Karthik B Jeganathan; Naomi Hamada; Jan Grasic; David Friedman; Jeremy T Stutchman; Ismail Can; Masakazu Hamada; Do Young Lim; Jeong-Heon Lee; Tamas Ordog; Remi-Martin Laberge; Virginia Shapiro; Darren J Baker; Hu Li; Jan M van Deursen
Journal:  Science       Date:  2021-10-29       Impact factor: 63.714

3.  NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.

Authors:  Dandan Li; Wenhao Zhao; Xinyu Zhang; Hanning Lv; Chunhong Li; Lichun Sun
Journal:  Clin Epigenetics       Date:  2021-05-17       Impact factor: 6.551

Review 4.  Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy.

Authors:  Jenniffer Linares; Juan A Marín-Jiménez; Jordi Badia-Ramentol; Alexandre Calon
Journal:  Front Cell Dev Biol       Date:  2021-01-22

5.  A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs.

Authors:  Kelsey E Huntington; Anna Louie; Lanlan Zhou; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2021-09-28

6.  CXCL14 facilitates the growth and metastasis of ovarian carcinoma cells via activation of the Wnt/β-catenin signaling pathway.

Authors:  Li-Na Gao; Man Hao; Xiao-Hui Liu; Li Zhang; Yan Dong; Yu-Fang Zhang; Xiao-Chun He
Journal:  J Ovarian Res       Date:  2021-11-17       Impact factor: 4.234

Review 7.  Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer.

Authors:  Yitong Li; Zhenmei Chen; Jiahao Han; Xiaochen Ma; Xin Zheng; Jinhong Chen
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

8.  Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors.

Authors:  Daniela Gasparotto; Marta Sbaraglia; Sabrina Rossi; Davide Baldazzi; Monica Brenca; Alessia Mondello; Federica Nardi; Dominga Racanelli; Matilde Cacciatore; Angelo Paolo Dei Tos; Roberta Maestro
Journal:  JCI Insight       Date:  2020-11-19

Review 9.  Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour.

Authors:  Alejandro Álvarez-Artime; Belén García-Soler; Rosa María Sainz; Juan Carlos Mayo
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

10.  CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.

Authors:  Tong Lin; E Zhang; Pei-Pei Mai; Ying-Zhao Zhang; Xiang Chen; Li-Sheng Peng
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.